PMID- 12296472
OWN - NLM
STAT- MEDLINE
DCOM- 20021114
LR  - 20181130
IS  - 0970-258X (Print)
IS  - 0970-258X (Linking)
VI  - 15
IP  - 4
DP  - 2002 Jul-Aug
TI  - Evaluation of minimal residual disease in patients with chronic myeloid leukaemia 
      on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ 
      hybridization.
PG  - 195-8
AB  - BACKGROUND: Chronic myeloid leukaemia (CML) is a haematopoietic malignancy 
      characterized by the presence of the Philadelphia (Ph) chromosome that results 
      from balanced reciprocal translocation between chromosomes 9 and 22 leading to 
      the formation of the bcr/abl fusion gene. Studies have shown that 
      interferon-alpha (IFN-alpha) therapy induces both cytogenetic (reduction in Ph+ 
      cells) and molecular response (reduction in the bcr/abl positive cells) in a 
      large proportion of patients, thereby improving their prognosis and survival. 
      There are no reports available from India on the clinical management of CML 
      patients using IFN-alpha therapy and molecular methods for the evaluation of 
      residual disease. We evaluated the efficacy of IFN-alpha 2b therapy bysequential 
      cytogenetic and molecularanalysis. METHODS: Karyotypingwas done from G-banded 
      metaphases obtained from 24-hour culture of bone marrow aspirates of 45 patients. 
      Cytogenetic analysis was repeated at intervals of 4-6 months during the course of 
      IFN-alpha therapy. Dual-colour fluorescence in situ hybridization (FISH) analysis 
      using specific probes for bcr and abl genes was done to assess the molecular 
      response. RESULTS: Eight patients achieved complete cytogenetic response with no 
      Ph+ cells. Using FISH analysis, 4 of these patients were negative for the fusion 
      gene implying a complete response, while the remaining 4 patients showed bcr/abl 
      fusion signals that represent residual disease. CONCLUSION: Our study emphasizes 
      the need for sequential cytogenetic and molecular analysis in the management of 
      patients with CML and for the evaluation of minimal residual disease in patients 
      on IFN-alpha therapy.
FAU - Talwar, Rashmi
AU  - Talwar R
AD  - All India Institute of Medical Sciences, Ansari Nagar, New Delhi.
FAU - Choudhry, V P
AU  - Choudhry VP
FAU - Jobanputra, Vaidehi
AU  - Jobanputra V
FAU - Kucheria, Kiran
AU  - Kucheria K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Natl Med J India
JT  - The National medical journal of India
JID - 8809315
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 04079A1RDZ (Cytarabine)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cytarabine/administration & dosage
MH  - Cytogenetic Analysis
MH  - Female
MH  - Fusion Proteins, bcr-abl/*analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/genetics/pathology
MH  - Male
MH  - Neoplasm, Residual
MH  - Philadelphia Chromosome
MH  - Recombinant Proteins
EDAT- 2002/09/26 06:00
MHDA- 2002/11/26 04:00
CRDT- 2002/09/26 06:00
PHST- 2002/09/26 06:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/09/26 06:00 [entrez]
PST - ppublish
SO  - Natl Med J India. 2002 Jul-Aug;15(4):195-8.